Thanks to those CARs, the T-lymphocytes acquire the following novel, critically important activities: (i) CAR-T cells become able to target a specific molecule ligand (e.g., CD19) exposed on the surface of cancer cells, and (ii) CAR-T cells aim to kill target cancer cells after their CARs bind to the corresponding ligands on the surface of cancer cells. Here, CD19 is linked to cancer.